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ABSTRACT
The diagnosis of Chagas disease is based on the detection of Trypanosoma cruzi (T. 
cruzi)-specific antibodies. Nonetheless, there is concern about the sensitivity of current 
serological assays due to reports of T. cruzi PCR positivity among seronegative individuals. 
The aim of this study was to evaluate if T. cruzi seronegative infections occur in endemic 
areas. We recruited 2,157 individuals that were identified as having Chagas disease in a public 
health system database of an endemic region in Brazil. All participants were interviewed 
and 2,091 had a sample collected for serological and PCR testing. From these, 149 (7.1%) 
had negative serological results. PCR was positive in 610 samples (31.4%) of the 1,942 
seropositive samples but in none of the 149 samples from seronegative participants. True T. 
cruzi seronegative infections seem to be rare (95% CI 0-3.7) and should not be a concern 
for blood supply, which relies on antibody screening. 
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INTRODUCTION
Chagas disease is caused by the parasite Trypanosoma cruzi1. In recent years, 
despite the progressive decline of the estimated incidence and prevalence of Chagas 
disease, it remains one of the world’s most neglected diseases, with an estimated 
5.7 million infected people mostly in 21 resource-limited countries in America2.
The diagnosis is based on serological assays because parasitemia is in general 
low or undectectable during the chronic phase of the infection. The earliest 
tests developed for blood screening in Latin America had low sensitivity and 
reproducibility3. Consequently, for many years, countries like Brazil required the 
use of parallel serological tests for T. cruzi blood screening4.
Low reacting samples may not be detectable by all serological assays. This 
situation is commonly identified by donor screening in Latin American countries 
and in the US and these donations could be missed by some assays and represent 
a threat to blood supply5-8. In this context, it is reassuring that parasitemia is rarely 
detected by sensitive PCR tests performed on DNA derived from large volumes 
of blood samples from donors with low antibody titers, suggesting that they may 
represent resolved infections with waning antibodies9.
Another possible threat is the presence of so-called “serosilent infections”, in which 
parasitemia is detectable in seronegative individuals10-12. Rare cases of “serosilent 
infection” were previously described for HIV and HCV and, in general, they are 
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related to individuals with poor immune response13. In a 
previous study, we evaluated the frequency of seronegative 
infections by testing 500 seronegative blood donors from 
endemic regions in Brazil by a sensitive PCR testing14. 
In the present study, to further investigate the frequency 
of seronegative T. cruzi infections, we performed a sensitive, 
high-volume input T. cruzi PCR assay on coded samples 
from 2,091 individuals with cardiac abnormalities from a 
region in Brazil with a high prevalence of Chagas Disease. 
We found 149 (7%) seronegative individuals but none of 
them tested positive by PCR, showing that if seronegative 
parasitemic infections exist, they are very rare.
METHODS
Study design
This study is part of the Sao Paulo-Minas Gerais 
Tropical Medicine Research Center (SaMi-Trop), a 
prospective cohort of patients with Chagas disease15. 
Selection of patients was made by using the database of the 
Telehealth Network of Minas Gerais, a program designed 
to support primary care in Minas Gerais State that collects 
and analyses patients’ ECG and clinical data16. Patients 
living within a limited region in the Northern part of 
Minas Gerais State that has a high prevalence of T. cruzi 
infection were included if they had ECG abnormalities 
and self-reported Chagas Disease. From 4,689 eligible 
patients, 2,157 individuals were recruited, interviewed 
and submitted to ECG and sample collection. From these, 
we obtained blood samples and performed serology and 
PCR in 2,091 individuals, which were included in this 
study. All these subjects signed the informed consent 
for additional testing including PCR. This study was 
approved by National Council Research Ethics – CONEP 
(Certificate of presentation for Ethical Appreciation – 
CAAEE Nº 00580612.8.0000.0065). 
Blood processing 
At the time of the enrollment interview, 8 mL of 
peripheral blood were collected in serum separator 
tubes (SST) for serological analyses and 12 mL of 
ethylenediaminetetraacetic acid (EDTA)-anticoagulated 
blood were collected and immediately mixed with an equal 
volume of 6 M guanidine/HCl-0.2M EDTA solution for 
PCR. These samples were aliquoted and frozen in Brazil 
at −20 ºC. Aliquots of guanidine-lysed blood samples were 
shipped to the Blood Systems Research Institute (San 
Francisco, CA, USA) on dry ice, followed by maintenance 
at −70 ºC. All testing was performed on coded samples.
Serology testing
All samples were initially screened using the 
chemiluminescent microparticle immunoassay (ChIA) 
method for detection of antibodies to T. cruzi (Architect 
Chagas, Abbott Laboratories, Wiesbaden Germany). 
Samples with negative results were retested with two other 
enzyme immunoassays (EIAs: Chagatest v.4, Wiener and 
Chagas, Diasorin). We classified ChIA negative samples as 
inconclusive when they were reactive on one or both of the 
antibody assays used for retesting.
PCR procedure
The target-capture (TC) real-time (RT) PCR assay used 
in this study was developed based on the PCR method 
described by Pyron et al.17, that targets satellite T. cruzi 
DNA. The DNA extraction was improved through the use 
of a TC step that employed magnetic beads coated with a 
T. cruzi-specific 20-mer capture oligonucleotide9.
Two replicate TC-PCR assays were performed and 
results were interpreted as positive if both replicates were 
positive. If only one replicate result was positive, the 
sample was considered as PCR inconclusive, and another 
aliquot of this sample was processed in four replicates. The 
results were then considered positive if at least two of the 
four additional replicates were positive. Quantification of 
parasitemia was based on a standard curve derived from 
cultured parasites spiked into whole blood prior to lysis, 
with a detection range of 0.1 to 10,000 parasites/mL9,14 
Statistical analysis
Data are presented as means and standard deviations 
or as numbers and percentages. Shapiro-Wilk tests were 
used to verify data normality. ANOVA tests were used for 
comparison of antibodies levels with parasitemia. Chi-
square tests and/or Fisher exact tests were used to compare 
categorical variables between groups and Kruskall-Wallis 
tests were used to compare continuous variables between 
groups. A value of p < 0.05 was considered significant.
RESULTS
The EIA and PCR results obtained by testing 2,091 
coded samples are summarized in Figure 1. One-hundred 
fifty-eight patients’ samples had negative results by the 
Architect ChIA antibody test (ARCHITECT Chagas - 
Abbott, Illinois USA). From these, nine had reactive 
results with at least one of the other two EIA assays (Kit 
Chagatest – ELISA recombinant v.4.0 -Wiener, Rosario, 
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Argentine and Kit Test ELISA Chagas III – (Grupo Bios 
S.A – Diasorin, Santiago, Chile) and were classified as 
serologically inconclusive.
None of the 158 coded samples with negative or 
inconclusive ChIA/EIA results were positive by PCR. 
In contrast, 610 (31.4%) of the 1,942 ChIA seropositive 
samples were PCR positive, (p<0.001 for comparison with 
the EIA-negative samples). The concentration of parasites 
detected by PCR ranged from 0.1 to 667 parasites/mL. 
Table 1 summarizes the epidemiologic and clinical 
characteristics of patients, as well as PCR results, of 
seropositive and seronegative participants. Of the 149 
seronegative individuals, 110 (74%) reported a previous 
Chagas diagnosis during the study interview, 64 (43%) 
referred at least one relative with a diagnosis of Chagas 
disease, and 26 indicated that their mothers were T. 
cruzi positive. Only nine participants stated that they had 
previously received benznidazole (BZN) treatment. Given 
that we have screened 2,091 individuals, we can state that 
the prevalence of seronegative infection in the population 
may vary from 0 to 3.7, with a 95% confidence interval. 
DISCUSSION
In this study, we could not find evidence of T. cruzi 
seronegative infection after rigorous serological and 
PCR testing of coded samples from 2,091 individuals 
that disclosed Chagas disease in their clinical histories 
and presenting ECG test abnormalities in the primary 
care center. Seronegative results using a combination of 
sensitive antibody assays were found in 7% of the patients, 
but none of them tested positive by PCR for T. cruzi. PCR 
was positive in only 31.4% of the coded samples from 
seropositive individuals.
Previous reports have reported seronegative T. cruzi 
infections, raising concerns on the sensitivity of serological 
assays for diagnostics and blood bank donor screening. 
Salomone et al.12 evaluated 194 subjects from endemic 
regions, including 110 sent from a cardiology clinic. In this 
sample, 80 patients were negative by the three serological 
tests used (indirect-hemagglutination, immunofluorescence 
and ELISA), and of those, 12 (15%) were positive by 
PCR. In that study, PCR was positive in 24 of 114 (21%) 
seropositive patients. Of note, no control group derived 
from a low risk population was tested to determine false 
positive rates of the PCR assay. Gomes et al.11, tested 100 
T. cruzi-infected individuals from highly endemic areas by 
hemagglutination, EIA and PCR. PCR was positive in 66 
(84%) of the 79 seropositive samples and in 10 (48%) of 
21 seronegative individuals. They also evaluated samples 
from 13 seronegative controls that were not from endemic 
Table 1 – Epidemiological and clinical characteristics and PCR testing results of Chagas disease patients from endemic areas in 
Minas Gerais State, highlighting negative versus positive serological results. 
Variable Seronegative individuals 
n=149 (%)
Seropositive individuals 
n=1942 (%) P-value
Age mean ±SD, 63 ± 14.4 59 ± 12.7 <0.001a
Male 63 (42.3) 632 (32.5) 0.015 b
Mother with Chagas disease 26 (17.4) 369 (19) 0.641b
Other family member with Chagas disease 64 (42.9) 1,002 (51.6) 0.042b
Self-reported Chagas disease 110 (73.8) 1,870 (96.3) <0.001b
Benznidazole treatment 9 (6.0) 492 (25.3) <0.001b
Positive PCR assay 0 (0) 610 (31.4) <0.001c
a Mann Whitney test; b Chi-square test; cFisher exact test.
Figure 1 - Serological and PCR results of studied patients. 
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areas, and all of them were PCR negative. More recently, 
Batista et al.10 evaluated 41 seronegative and serologically 
inconclusive cases with mega-esophagus, and reported 31 
(76%) as PCR positive. In this study PCR was positive in 
42 (93%) of the 45 seropositive individuals, and in none of 
the 18 seronegative controls. 
Different factors must be considered when comparing 
serology and PCR results. Serological methods have 
improved over the years as a consequence of the use 
of recombinant proteins. Nowadays, the main problem 
seems to be cross-reactions with other diseases, especially 
leishmaniasis. However, PCR results still show high 
variability, depending on T. cruzi lineages and amplified 
target regions. Another important issue is that parasitemia 
fluctuates in patients with chronic Chagas disease over the 
prolonged course of infection18.
It is important to emphasize that our study has 
limitations. Here, 492 (25%) of the seropositive individuals 
had been previously treated with BZN. Our studied 
population was older than the patients in other studies 
such as the Benefit trial that yielded a higher rate of PCR 
positivity (66.2%)19. Nevertheless, if the prevalence of 
“serosilent” infection in the study population was 1%, we 
would have had approximately 20 “serosilent” individuals 
within the 149 ones tested as seronegative. Given the 31.3% 
of detection rate of T. cruzi DNA by our TC-PCR assay in 
coded samples from this cohort seropositive participants, 
the PCR test would have detected six cases, but none was 
observed. In fact, we can also state with 95% CI that the 
prevalence is below 3.7%.
Some of these factors may account for the fact that the 
above-mentioned studies detected “serosilent” infections, 
while this study and the previous one performed by our 
group on blood donor samples did not. The seronegative 
individuals in our study were older and hence may have 
resolved infections and seroreverted. We used sensitive 
blood bank ChIA and EIAs, which are currently used 
for screening and diagnosis, while the other studies that 
reported “serosilent” infections used less sensitive assays 
such as hemaglutination, immunofluorescence or earlier 
versions of EIAs. Moreover, given the natural history of 
Chagas disease, i.e. the long incubation period before 
symptoms develop, and the difficulty of tracking and 
associating donors with recipients long after a transfusion 
event, it is reassuring that no unambiguous case report of 
transfusion-transmission of Chagas from a seronegative 
infected individual has taken place, even if this type of 
transmission does actually occur. 
In conclusion, our data on the absence of seronegative 
infections in a large cohort of high-risk clinical cases 
confirm our previous results from a retrospective Brazilian 
blood donor study. These findings are reassuring and 
indicate that donor serological screening tests are highly 
sensitive in detecting antibodies against T. cruzi.
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